vs
Side-by-side financial comparison of ARCBEST CORP (ARCB) and BioNTech SE (BNTX). Click either name above to swap in a different company.
BioNTech SE is the larger business by last-quarter revenue ($1.5B vs $998.8M, roughly 1.5× ARCBEST CORP). ARCBEST CORP runs the higher net margin — -0.1% vs -1.9%, a 1.8% gap on every dollar of revenue.
ArcBest Corporation is a leading U.S.-based logistics and transportation solutions provider. It offers end-to-end supply chain services including less-than-truckload freight shipping, full truckload services, warehousing, expedited delivery, and customized logistics consulting, serving enterprise, small business, and government clients across North America and select global markets.
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
ARCB vs BNTX — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $998.8M | $1.5B |
| Net Profit | $-1.0M | $-28.7M |
| Gross Margin | — | — |
| Operating Margin | 0.3% | -3.1% |
| Net Margin | -0.1% | -1.9% |
| Revenue YoY | 3.3% | — |
| Net Profit YoY | -133.1% | — |
| EPS (diluted) | $-0.05 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $998.8M | — | ||
| Q4 25 | $972.7M | — | ||
| Q3 25 | $1.0B | $1.5B | ||
| Q2 25 | $1.0B | $260.8M | ||
| Q1 25 | $967.1M | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.1B | $1.2B | ||
| Q2 24 | $1.1B | — |
| Q1 26 | $-1.0M | — | ||
| Q4 25 | $-8.1M | — | ||
| Q3 25 | $39.3M | $-28.7M | ||
| Q2 25 | $25.8M | $-386.6M | ||
| Q1 25 | $3.1M | — | ||
| Q4 24 | $29.0M | — | ||
| Q3 24 | $100.3M | $198.1M | ||
| Q2 24 | $46.9M | — |
| Q1 26 | 0.3% | — | ||
| Q4 25 | -0.8% | — | ||
| Q3 25 | 5.2% | -3.1% | ||
| Q2 25 | 3.6% | -192.1% | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | 12.7% | 0.8% | ||
| Q2 24 | 4.5% | — |
| Q1 26 | -0.1% | — | ||
| Q4 25 | -0.8% | — | ||
| Q3 25 | 3.7% | -1.9% | ||
| Q2 25 | 2.5% | -148.2% | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 2.9% | — | ||
| Q3 24 | 9.4% | 15.9% | ||
| Q2 24 | 4.4% | — |
| Q1 26 | $-0.05 | — | ||
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $1.72 | — | ||
| Q2 25 | $1.12 | — | ||
| Q1 25 | $0.13 | — | ||
| Q4 24 | $1.21 | — | ||
| Q3 24 | $4.23 | — | ||
| Q2 24 | $1.96 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $86.4M | — |
| Total DebtLower is stronger | $223.7M | — |
| Stockholders' EquityBook value | $1.3B | — |
| Total Assets | $2.5B | — |
| Debt / EquityLower = less leverage | 0.17× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $86.4M | — | ||
| Q4 25 | $124.2M | — | ||
| Q3 25 | $132.6M | — | ||
| Q2 25 | $139.7M | — | ||
| Q1 25 | $98.7M | — | ||
| Q4 24 | $157.2M | — | ||
| Q3 24 | $191.1M | — | ||
| Q2 24 | $260.5M | — |
| Q1 26 | $223.7M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $214.1M | — | ||
| Q2 25 | $241.4M | — | ||
| Q1 25 | $214.2M | — | ||
| Q4 24 | $189.1M | — | ||
| Q3 24 | $180.5M | — | ||
| Q2 24 | $203.6M | — |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.2B | — |
| Q1 26 | $2.5B | — | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.4B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — |
| Q1 26 | 0.17× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.16× | — | ||
| Q2 25 | 0.19× | — | ||
| Q1 25 | 0.17× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.17× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
